Angiotensin receptor blockers: Pharmacology and clinical significance

Journal of the American Society of Nephrology

Volumn 10, Issue 4 SUPPL., 1999, Pages

  Mimran, Albert ^a,b   Ribstein, Jean ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ATENOLOL; CANDESARTAN; CANDESARTAN HEXETIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; SARALASIN; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; COUGHING; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0032904001     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Arakawa K: Serine protease angiotensin systems. J Hypertens 14[Suppl 5]: 3S-7S, 1996
2. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JM, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251, 1993
3. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PB: Nonpetide angiotensin II receptor antagonists: The next generation in antihypertensive therapy. J Med Chem 39: 625-656, 1996
4. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S, Meffert S, Stoll M, Stroth U, Zhu YZ: Angiotensin receptors. J Hypertens 14[Suppl 5]: S95-S103, 1996
5. Markham A, Goa KL: Valsartan: A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54: 299-311, 1997
6. Morimoto S, Ogihara T: TCV-116: A new angiotensin II type 1 receptor antagonist. Cardiovasc Drug Res 12: 153-164, 1994
7. de Zeeuw D, Remuzzi G, Kirch W: Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 11[Suppl 2]: S37-S42, 1997
8. Christen Y, Waeber B, Nussberger J, Prochet RN, Borland RM, Lee RJ, Maggon K, shum L, Timmermans PBMWM, Brunner HR: Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: Inhibition of presser response to exogenous angiotensin I and II. Circulation 83: 1333-1342, 1991
9. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 25: 14-21, 1995
10. Ribstein J, Picard A, Armagnac C, Sissmann J, Mimran A: Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive man. J Cardiovasc Pharmacol 1999, in press
11. Gandhi SK, Ryder DH, Brown NJ: Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 28: 961-966, 1996
12. Cockroft JR, Sciberras DG, Goldberg MR, Ritter JM: Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 22: 579-584, 1993
13. 1) receptor antagonist: A review of its efficacy and safety in essential hypertension. Pharmacol Ther 74: 181-194, 1997
14. Sever PS: Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 11[Suppl 2]: S91-S95, 1997
15. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H: Dose-related efficacy of irbesartan for hypertension: An integrated analysis. Hypertension 31: 1311-1316, 1998
16. McClellan KJ, Balfour JA: Eprosartan. Drugs 55: 713-718, 1998
17. Gradman AH, Arcuri KE, Goldberg KI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS: A randomized, placebo-controlled, double-blind parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 25: 1345-1350, 1995
18. Weber MA, Byyny RL, Pratt H, Faison EP, Snavely DB, Goldberg AI, Nelson EB: Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 155: 405-411, 1995
19. Andersson OK, Neldam S: The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 7: 53-59, 1998
20. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E, for the Irbesartan/Losartan Study Investigators: Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 11: 445-453, 1998
21. Laakso M, Karjalainen L, Lempiäinen-Kuosa P: Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 28: 392-396, 1996
22. Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, Miyazaki Y, Hirata A, Ura N, Nakagawa M: Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed rats and essential hypertensives. Am J Hypertens 8: 353-357, 1995
23. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 117: 234-242, 1992
24. Lacourciere Y, Brunner H, Irwin R, Karlberg BE, Ramsay BE, Snavely DB, Dobbins TW, Faison EP, Nelson EB, and the Losartan Cough Study Group: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 12: 1387-1393, 1994
25. Sharma PK, Yium JJ: Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 90: 552-553, 1997
26. Heeringa M: Reversible dysgeusia attributed to losartan [Abstract]. Ann Intern Med 129: 72, 1998
27. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Waeber B, Brunner HR: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25[Part I]: 602-609, 1995
28. Price DA, De'Oliveira M, Fisher NDL, Hollenberg NK: Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 30[Part I]: 240-246, 1997
29. Burnier M, Brunner HR: Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Exp Nephrol 4[Suppl 1]: 41-46, 1996
30. Fauvel JP, Berra N, Pozet N, Madonna O, Zech P, Laville M: Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 28: 259-263, 1996
31. Pechere-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M: Renal response to the angiotensin II receptor subtype I antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 16: 385-393, 1998
32. Kawabata M, Takabatake T, Ohta H, Nakamura S, Kara H, Ohta K, Takakuwa H, Han WH, Kobayashi KI: Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press 3[Suppl 5]: 117-121, 1994
33. Buter H, Navis G, de Zeeuw D, de Jong P: Renal hemodynamic effect of candesartan in normal and impaired renal function in humans. Kidney Int 52[Suppl 63]: S185-S187, 1997
34. Gansevoort RT, de Zeeuw D, de Jong P: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 45: 861-867, 1994
35. Nielsen S, Dollerup J, Nielsen B, Jensen HE, Mogensen CE: Losartan reduces albuminuria in patients with essential hypertension: An enalapril controlled 3 months study. Nephrol Dial Transplant 12[Suppl 2]: 19-23, 1997
36. 1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 38: 437-441, 1998
37. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K: Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 6: 28-32, 1993
38. Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP: Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med 308: 377-381, 1983
39. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA: Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 115:513-519, 1991
40. Demeilliers B, Jover B, Mimran A: Contrasting renal effects of chronic administrations of enalapril and losartan on one-kidney, one clip hypertensive rats. J Hypertens 16: 1023-1029, 1998
41. Arzilli F, Favilla S, Motolese M, Peruzzi E, Oddou-Stock P, Salvetti A: Valsartan, a new angiotensin II antagonist: Tolerability and effects on renal function in patients with renovascular arterial hypertension. High Blood Press 6: 153-158, 1997
42. Mimran A,· Ribstein J, DuCailar G: Comparison of the acute renal effect of losartan and captopril in atheromatous renovascular disease [Abstract]. Am J Hypertens 11: 47A, 1998
43. Holm EA, Randlov A, Strandgard S: Acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis. Blood Press 5: 360-362, 1996
44. Missouris CG, Ward DE, Eastwood JB, MacGregor GA: Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney. Heart 77: 391-392, 1997
45. Ostermann M, Goldsmith DJA, Doyle T, Kingswood JC, Sharpstone P: Reversible acute renal failure induced by losartan in a renal transplant recipient. Postgrad Med J 73: 105-107, 1997
46. Cuspidi C, Lonati L, Sampieri L, Valagussa L, Macca G, Leonetti G, Zanchetti A: Effects of losartan on blood pressure and left ventricular mass in essential hypertension. High Blood Press 7: 75-79, 1998
47. Tedesco MA, Ratti G, Aquino D, Limongelli G, Di Salvo G, Mennella S, Galzerano D, Iarussi D, Iacono A: Effects of losartan on hypertension and left ventricular mass: A long-term study. J Hum Hypertens 12: 505-510, 1998
48. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of the ELITE Study Investigators: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747-752, 1997